Recommended dose of 800 mg (4 x 200 mg tablets) taken orally, twice daily, until disease progression or unacceptable toxicity.1

NDC number (10 digit): 72607-100-00
NDC number (11 digit): 72607-0100-00
How supplied: 240-count bottle
NDC=National Drug Code


1st dose

Tablets are not
actual size.
2nd dose

Swallow tablets whole. Do not cut, crush, or chew tablets.
Do not take an additional dose if a dose is missed or vomiting occurs after taking TAZVERIK®, but continue with the next scheduled dose.1
TAZVERIK is an oral therapy that works through an epigenetic mechanism. It may take time for your patients to respond to TAZVERIK.1,2
- For patients who experienced an overall response in the clinical trial, the median time to response was:
3.9 months (range: 1.6 to 16.3) for patients with WT EZH2.1
and
3.7 months (range: 1.6 to 10.9)
for patients with MT EZH2.1
Recommended dose of 800 mg (4 x 200 mg tablets) taken orally, twice daily, until disease progression or unacceptable toxicity.1

1st dose

Tablets are not actual size.
2nd dose

Swallow tablets whole. Do not cut, crush, or chew tablets.
Do not take an additional dose if a dose is missed or vomiting occurs after taking TAZVERIK®, but continue with the next scheduled dose.1

NDC number (10 digit): 72607-100-00
NDC number (11 digit): 72607-0100-00
How supplied: 240-count bottle
NDC= National Drug Code
TAZVERIK® is an oral therapy that works through an epigenetic mechanism.
It may take time for your patients to respond to TAZVERIK.1,2
For patients who experienced an overall response in the clinical trial, the median time to response was:
3.9 months (range: 1.6 to 16.3) for patients with WT EZH2.1
and
3.7 months (range: 1.6 to 10.9) for patients with MT EZH2.1
WT=wild type; EZH2=enhancer of zeste homolog 2; MT= mutant type.
References: 1. TAZVERIK (tazemetostat) Prescribing Information. Cambridge, MA: Epizyme, Inc., July 2020. 2. Sermer D, Pasqualucci L, Wendel HG, et al. Emerging epigenetic-modulating therapies in lymphoma. Nat Rev Clin Oncol. 2019;16(8):494-507.